Decreased lumbar spine trabecular bone score (TBS), a DXA-derived image texture measurement, is a risk factor for major osteoporotic fracture (MOF) and hip fracture (HF) independent of ten-year fracture probability estimated using FRAXR. We determined how often applying the TBS adjustment to fracture probability altered treatment qualification. Using a population-based registry containing all clinical DXA results for Manitoba, Canada, we identified 34,316 women with baseline spine and hip DXA, FRAX-based fracture probability measurements (computed with femoral neck bone mineral density), lumbar spine TBS, and minimum 5 years of observation (mean 8.7 years). Population-based health services data were used to identify incident non-traumatic MOF and HF in 3,503 and 945 women, respectively. Baseline MOF and HF probabilities were estimated using FRAX before and after applying the TBS adjustment. Risk recategorization was assessed using net reclassification improvement (NRI) for individual FRAX-based intervention criteria and three national clinical practice guidelines (CPGs) (US National Osteoporosis Foundation, Osteoporosis Canada, UK National Osteoporosis Guideline Group). Overall proportions of women reclassified with the TBS adjustment to FRAX were small (less than 5%) with over 90% of the reclassification occurring close to the intervention threshold. For women close to an intervention cut-off reclassification rates ranged from 9.0% to 17.9%, and were <1%
otherwise. There was a small but significant improvement in overall NRI for all individual FRAX-based intervention criteria (range 0.007 to 0.018) and all three national CPGs (range 0.008 to 0.011). NRI was larger in women below age 65 years (up to 0.056 for hip fracture). In summary, a small but significant improvement in MOF and HF risk assessment was seen by using lumbar spine TBS to adjust FRAX probability. An improvement in risk reclassification was observed for CPGs from three different countries, with almost all of the benefit seen in individuals close to an intervention threshold. 
Abstract:
Decreased lumbar spine trabecular bone score (TBS), a DXA-derived image texture measurement, is a risk factor for major osteoporotic fracture (MOF) and hip fracture (HF) independent of ten-year fracture probability estimated using FRAX R . We determined how often applying the TBS adjustment to fracture probability altered treatment qualification. Using a population-based registry containing all clinical DXA results for Manitoba, Canada, we identified 34,316 women with baseline spine and hip DXA, FRAX-based fracture probability measurements (computed with femoral neck bone mineral density), lumbar spine TBS, and minimum 5 years of observation (mean 8.7 years). Population-based health services data were used to identify incident non-traumatic MOF and HF in 3,503 and 945 women, respectively. Baseline MOF and HF probabilities were estimated using FRAX before and after applying the TBS adjustment. Risk re-categorization was assessed using net reclassification improvement (NRI) for individual FRAX-based intervention criteria and three national clinical practice guidelines (CPGs) (US National Osteoporosis Foundation, Osteoporosis Canada, UK National Osteoporosis Guideline Group). Overall proportions of women reclassified with the TBS adjustment to FRAX were small (less than 5%) with over 90% of the reclassification occurring close to the intervention threshold.
For women close to an intervention cut-off reclassification rates ranged from 9.0% to 17.9%, and were <1% otherwise. There was a small but significant improvement in overall NRI for all individual FRAX-based intervention criteria (range 0.007 to 0.018) and all three national CPGs (range 0.008 to 0.011). NRI was larger in women below age 65 years (up to 0.056 for hip fracture).
In summary, a small but significant improvement in MOF and HF risk assessment was seen by using lumbar spine TBS to adjust FRAX probability. An improvement in risk reclassification was observed for CPGs from three different countries, with almost all of the benefit seen in individuals close to an intervention threshold. 
Introduction
Trabecular bone score (TBS) was introduced as a method to assess the texture of trabecular bone using a conventional DXA image (1;2) Cross-sectional studies, longitudinal studies and a recent meta-analysis of multiple prospective cohorts have demonstrated that reduced TBS correlates with increased fracture risk (3;4) . More recently, lumbar spine TBS was shown to be a risk factor for osteoporotic fracture and also for risk of death independent of FRAX clinical risk factors and femoral neck bone mineral density (BMD) (5). An algorithm was developed to adjust fracture probability to account for the effect of TBS (6) and this approach has subsequently been independently validated in a meta-analysis of international cohorts (7).
Several authors have examined the value of combining TBS with BMD (with or without additional risk factors) for fracture risk prediction, with most of these studies reporting the increase in area under the receiver operating characteristic curve (AUC) (8) (9) (10) (11) . On the whole, inclusion of TBS led to small increases in AUC; however, as has been pointed out (12;13), the addition of novel factors in risk prediction models can result in deceptively small changes in the AUROC despite an overall improved risk classification. For these purposes, it has been suggested that reclassification analyses may serve as a more appropriate metric for assessing the clinical impact of an additional factor in risk classification models (14;15).
Net reclassification improvement (NRI) is a technique applicable when dealing with risk prediction models (16 
Measurement of BMD and TBS
All DXA scans were performed and analyzed in accordance with the manufacturer's recommendations. BMD measurements were recorded for the lumbar spine BMD for L 1 through L 4 (L 1 -L 4, ) and the femoral neck. Hip T-and Z-scores were calculated using the National Health and Nutrition Examination Survey (NHANES) III white female reference values (21) . For the lumbar spine, manufacturer reference data for white US women were used. The resulting data approximated a normal distribution. Instruments were cross-calibrated using anthropomorphic phantoms. No clinically significant differences were identified; therefore, all analyses are based on unadjusted numerical results generated by the instrument. thereafter. Anonymous linkage of these databases to the BMD database was possible via a unique scrambled health identification number, thereby allowing for the creation of a longitudinal record of health services and outcomes. Longitudinal health service records were examined for the presence of fracture codes before and after BMD testing that were not associated with trauma codes using previously validated algorithms (22) . We required that hip and forearm fractures be accompanied by a site-specific fracture reduction, fixation, or casting code, which enhances the diagnostic and temporal specificity of an acute fracture.
FRAX and TBS-adjusted FRAX Calculations
The ten-year probabilities for MOF and for HF were calculated using the fracture risk assessment tool developed by the World Health Organization Collaborating Centre at Sheffield, Canadian version (FRAX® Desktop Multi-Patient Entry, version 3.7). Data required for calculating fracture probability with FRAX were assessed through a combination of data from the BMD registry, self-reported information at the time of BMD testing, hospital discharge abstracts, physician claims and a province-wide retail pharmacy database as previously described (23) .
Anthropomorphic data (height and weight) were measured at the time of DXA, and BMI was We then derived TBS-adjusted FRAX fracture probability for MOF and HF using the method previously described by McCloskey et al (6) . This procedure incorporates both competing mortality and an age-TBS interaction in the calculation. This resulted in both FRAX and TBS-adjusted FRAX fracture probabilities for MOF and HF in all subjects.
Treatment Qualification
Participants were categorized according to treatment qualification based on both the FRAX and TBS-adjusted FRAX probabilities using individual FRAX-based intervention criteria as well as clinical practice guidelines (CPGs) from three different countries -the US National Osteoporosis Foundation (NOF) (15), Canadian Osteoporosis guidelines (17) , and the UK National Osteoporosis Guideline Group (NOGG) (18) . Each of these guidelines suggests pharmacological intervention thresholds based, in part, on FRAX-predicted fracture risk, with specific intervention thresholds unique to each set of guidelines. Recommendations proposed by the US NOF suggest that therapy be initiated in those patients with BMD in the osteopenic range with 10-year risk of MOF ≥20% or risk of hip fracture ≥3%; additional criteria for treatment are prior non-trauma HF, vertebral fracture or osteoporotic T-score (15) . The Canadian Osteoporosis Guidelines recommend that pharmacological therapy be initiated in those patients with a ten-year risk of MOF in excess of 20%; additional criteria for treatment are prior non-trauma HF, vertebral fracture or multiple fracture episodes (17) . The NOGG (UK) also suggests initiating treatment with pharmacological agents based on the 10-year fracture risk, but with an intervention threshold that is dependent on age (equivalent to the risk for a woman with a prior fracture and no other risk factors); additional criteria for treatment are prior non-trauma fracture (18) . In routine practice, hip fracture probability is the primary determinant of FRAX-initiated treatment under the US NOF guideline, whereas MOF is the primary determinant of FRAX-initiated treatment under the Canadian and UK NOGG guidelines. Therefore, the primary analysis for the US NOF guideline was based upon HF, and was based upon MOF for the other guidelines.
Statistical Analysis
The NRI for moving from treatment qualification based upon FRAX-based probabilities without TBS to TBS-adjusted FRAX probabilities was determined for the individual FRAX criteria as well as the overall CPGs which include the additional criteria for treatment. NRI was computed separately for individuals with and without incident fractures, the sum reflecting the overall reclassification improvement. Given the known age-TBS interaction, we also performed analyses stratified by age (<65 years versus >65 years) (6) . The NRI was calculated as per the method detailed by Pencina et al (16) and reported as recommended by Leening et al (27) . For individuals who sustain a fracture in follow up, NRI fracture is the probability of moving to a higher FRAX risk category minus the probability of moving to a lower FRAX risk category. Conversely, for individuals who remain fracture-free in follow up, NRI non-fracture is the probability of moving into a lower FRAX risk category minus the probability of moving into a higher FRAX risk category. Values of NRI fracture and NRI non-fracture greater than zero indicate an improvement in risk classification, whereas negative values indicate worse risk classification. An asymptotic test of significance for the null hypothesis of NRI=0 based upon the multinomial distribution was performed (16) . In addition to NRI, the integrated discrimination improvement (IDI) was also determined where IDI can be viewed as a difference between improvement in average sensitivity corrected for any potential decrease in average (16) . The subgroup consisting of those patients whose FRAX results were close to an intervention threshold were tabulated separately, where this was operationally defined as: HF 3% ± 1%; MOF fixed 20% ± 5%; MOF age-dependent ± 5%.
Risk reclassification was also determined for subgroups based on femoral neck T-score (WHO category) and age (5 year groupings). Statistical analyses were performed using Statistica (Version 12.7, StatSoft, Inc., Tulsa, OK, USA). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 1 demonstrates the baseline characteristics of these subjects. On average, TBS was significantly lower in subjects with incident fractures than in those without. The majority of subjects with incident fractures had T-scores in the osteoporotic range. Inclusion of TBS in the fracture risk assessment did not significantly change the average MOF or HF risk calibration.
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The effect of including TBS in the fracture risk assessment on treatment reclassification is shown in Table 2 . Overall proportions of women reclassified with the TBS adjustment to FRAX were relatively small (less than 5%). However, for women close to an intervention cut-off treatment reclassification rates were much higher (range 9.0% to 17.9%), with reclassification rates <1% otherwise. Indeed, the vast majority of the treatment reclassification (range 90.0% to 98.4%) MOF, and also a larger effect for younger than older patients. The MOF intervention cutoff of 20% would be exceeded for a TBS value of 1.140 at age 50 but would need to be below 1.000 at age 75 years. The HF intervention cutoff of 3% would be exceeded for a TBS value of 1.210 at age 50 but would need to be 1.140 at age 75 years.
Discussion
Our results show that the use of TBS-adjusted FRAX leads to a small but significant improvement in HF and MOF risk assessment, as measured by NRI. The impact on risk reclassification was found to be greatest in those women close to an intervention threshold; however, the apparent impact on reclassification from including TBS in fracture risk assessment varied between the various guidelines examined in this study. Additionally, it was found that the utility of using TBS-adjusted FRAX was greatest in younger women (<65 years of age).
Previous analyses have shown that lumbar spine TBS is a predictor of fracture risk, independent of BMD, but its inclusion in a multivariate risk model leads to only a small improvement in performance as measured by the AUC (8;9;28-32). Prior studies have also examined the impact of TBS on risk assessment using NRI (10;31;33;34); however, the large NRI obtained in some of these studies raises concerns over model miscalibration as other performance metrics were non-significant (35) . The results of the current study are in line with those of Schousboe et al (36) who reported NRI in fracture cases of +0.033 (P<0.005) for TBS-adjusted fracture risk prediction in older men (MrOS), with only a very small net decrease for NRI in men without fracture. Our study was able to identify those patient populations for which incorporation of TBS in the risk assessment would be most useful in terms of impact on management -specifically, in those patients where conventional risk assessment placed them close to an intervention threshold. That this would be the case can be easily understood for a number of reasons. TBS adjustments are unlikely to move someone with a very low fracture risk to above a treatment threshold. Likewise, in those patients at very high risk of fracture and for whom treatment is already indicated, TBS will rarely be contributory.
An important result of our study is that the findings were not specific to any particular set of CPGs but were applicable to guidelines from three different countries. Indeed, the uniformity of this finding confirms the broad potential utility of TBS as a clinical tool for risk assessment and patient decision making. We found that the effect of applying TBS within the NOF guidelines was relatively less than with the Canadian and UK guidelines, presumably reflecting the multiple pathways to treatment eligibility under the former and the more limited role for FRAX probability assessment. In clinical practice, more than 90% of reclassifications arose when the assessed fracture probability (without TBS) lay within a narrow band around the intervention threshold (+1% for hip fracture probability and +5% for MOF probability). There is a useful analogy with the utility of BMD, which in the NOGG guidelines, limit the use of BMD in individuals close to the intervention threshold (37) .
Certain limitations of this study should be acknowledged. In particular, the population studied was from a clinical registry, and was composed largely of Caucasians, which may limit applicability to other populations. In addition, our subjects consisted entirely of women and whether these findings can be generalized to men is unknown; however, a recent meta-analysis has shown that TBS-adjusted FRAX performs similarly in men and women (4).
In summary, we have shown that incorporating TBS in the FRAX risk assessment paradigm led to an improvement in fracture risk classification, and was most effective in women close to an intervention threshold from the traditional assessment and in women below age 65 years. Data are mean ± SD for continuous variables, N (percent) for categorical variables. MOF = major osteoporotic fracture.
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Strengthening the Reporting of Observational Studies in Epidemiology
When reporting results of studies involving humans, the JBMR ® adheres to the STROBE statement, and authors must provide the information required by the STROBE checklist as adapted by JBMR. Since statistical analyses vary according to study design and prohibit the establishment of standard rules, the following guidelines are provided to assist authors in performing the most appropriate statistical analyses and reporting those results in accord with JBMR ® standards. The checklist aids authors in providing detailed information within their submission that meet a standard to achieve reproducibility and transparency of research, and assists reviewers in their effort determine whether the necessary information is present. If you have any questions, please contact us at jbmroffice@wiley.com.
JBMR® has adapted the STROBE Guidelines. To fulfill the guideline requirements for JBMR®, please select the statement that describes your study and fill out only the required STROBE checklist questions for the study. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Title/Abstract/Introduction-Indicate the study's design with a commonly used term in the title or the abstract. State specific objectives, including any prespecified hypotheses in introduction.
Methods-Present key elements of study design early in the paper. Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.
™ Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up. For matched studies, give matching criteria and number of exposed and unexposed
Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.
™ For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one groupX ™ Describe any efforts to address potential sources of bias ™ Explain how the study size was arrived at Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why ™ Describe all statistical methods, including those used to control for confounding. Describe any methods used to examine subgroups and interactions. ™ Explain how missing data were addressed ™ If applicable, explain how loss to follow-up was addressed ™ Describe any sensitivity analyses Results-Report numbers of individuals at each stage of study-numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed ™ Give reasons for non-participation at each stage ™ Indicate number of participants with missing data for each variable of interest ™ Summarize follow-up time (eg, average and total amount) Report numbers of outcome events or summary measures over time Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included. 
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™ Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. For matched studies, give matching criteria and the number of controls per case.
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™ Give the eligibility criteria, and the sources and methods of selection of participants
Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. ™ For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group ™ Describe any efforts to address potential sources of bias ™ Explain how the study size was arrived at Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why ™ Describe all statistical methods, including those used to control for confounding. Describe any methods used to examine subgroups and interactions. ™ Explain how missing data were addressed ™ If applicable, describe analytical methods taking account of sampling strategy ™ Describe any sensitivity analyses Results-Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing followup, and analyzed ™ Give reasons for non-participation at each stage ™ Indicate number of participants with missing data for each variable of interest Report numbers of outcome events or summary measures Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included.
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